Establishment of a Model to Predict the Prognosis of Endometrial Carcinoma Using Tumor-Infiltrating Lymphocytes Evaluated With Artificial Intelligence: A Retrospective Analysis

利用人工智能评估肿瘤浸润淋巴细胞建立预测子宫内膜癌预后的模型:一项回顾性分析

阅读:2

Abstract

BACKGROUND: The objective of this study was to establish a new model for predicting the prognosis of endometrial carcinoma (EC) using tumor-infiltrating lymphocytes (TILs) based on artificial intelligence (AI). METHODS: Patients with EC who were treated between 1989 and 2022 were included in this study. For each patient, one hematoxylin and eosin-stained slide containing the most invasive frontline of the tumor was selected and digitized. The area within a 500 μm width span, extending 250 μm toward the stroma and tumor from the manually annotated invasive frontline, was automatically annotated. The average number of lymphocytes per area (μm(2)) in the annotated area was calculated using AI. Patients were classified into the High-TIL and Low-TIL groups, and survival analysis was conducted. Four mismatch repair (MMR)-related proteins were evaluated using immunohistochemical staining. RESULTS: A total of 659 patients were included: 346 (52.5%) in the High-TIL group and 313 (47.5%) in the Low-TIL group. MMR deficiency was observed more frequently in the High-TIL group than in the Low-TIL group (p < 0.01). Progression-free survival (PFS) and overall survival (OS) were better in the High-TIL group than in the Low-TIL group (both p < 0.01). Multivariate analysis revealed that TIL status was a prognostic factor for PFS (hazard ratio [HR] (95% confidence interval [CI]) 0.61 (0.43-0.87); p < 0.01) and OS (HR (95% CI) 0.54 (0.33-0.86); p = 0.01). CONCLUSION: TILs evaluated using AI could accurately and significantly predict the prognosis of EC. Further studies are needed to establish new methods for evaluating TILs in ECs.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。